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Angelman syndrome (AS) is a neurodevelopmental disorder caused by maternal deletions or mutations of 
the ubiquitin ligase E3A (UBE3A) allele and characterized by minimal verbal communication, seizures, and 
disorders of voluntary movement. Previous studies have suggested that abnormal dopamine neurotransmis-
sion may underlie some of these deficits, but no effective treatment currently exists for the core features of AS. 
A clinical trial of levodopa (l-DOPA) in AS is ongoing, although the underlying rationale for this treatment 
strategy has not yet been thoroughly examined in preclinical models. We found that AS model mice lacking 
maternal Ube3a (Ube3am–/p+ mice) exhibit behavioral deficits that correlated with abnormal dopamine signal-
ing. These deficits were not due to loss of dopaminergic neurons or impaired dopamine synthesis. Unexpect-
edly, Ube3am–/p+ mice exhibited increased dopamine release in the mesolimbic pathway while also exhibiting 
a decrease in dopamine release in the nigrostriatal pathway, as measured with fast-scan cyclic voltammetry. 
These findings demonstrate the complex effects of UBE3A loss on dopamine signaling in subcortical motor 
pathways that may inform ongoing clinical trials of l-DOPA therapy in patients with AS.
Introduction
Angelman syndrome (AS) is a neurodevelopmental disorder char-
acterized by intellectual disability, profound language impair-
ment, seizures, and a propensity for a happy disposition (1–3). AS 
results from loss of function of the maternally inherited UBE3A 
allele at the 15q11-q13 locus (4–9). The UBE3A gene encodes a 
HECT domain E3 ubiquitin ligase (UBE3A, also known as E6AP) 
involved in protein degradation through the ubiquitin-protea-
some pathway (4, 10). Clinical treatment of AS commonly includes 
pharmacotherapy for seizures, problem behaviors, and motor dys-
function (11). Although treatments for AS are limited, a case study 
of 2 adults with AS found that levodopa (l-DOPA) administration 
dramatically improved resting tremor and rigidity (12), leading to 
a clinical trial of l-DOPA in individuals with AS (13).
There are few published studies validating the rationale for 
using l-DOPA to treat parkinsonian features in AS. AS model 
mice lacking maternal Ube3a (Ube3am–/p+ mice) were reported 
to have reduced dopamine cell number in the substantia nigra 
pars compacta (SNc) by 7 to 8 months of age (14). In Drosophila, 
UBE3A has been shown to regulate GTP cyclohydrolase I, an 
essential enzyme in dopamine biosynthesis (15). However, lit-
tle is known about the function of mesolimbic or nigrostriatal 
dopamine pathways in AS, which have vital roles in several of 
the behaviors or motor symptoms commonly managed with 
pharmacotherapy, including hyperactivity, impulsivity, tremor, 
and rigidity. A survey of psychoactive drugs used in patients 
with AS reported that the majority responded poorly to stimu-
lant medications (16), most of which act by increasing available 
extracellular dopamine levels.
We examined dopamine-dependent behaviors as well as dopa-
mine synthesis, content, and release in the mesolimbic and nigro-
striatal pathways of AS model mice. Ube3am–/p+ mice were more 
sensitive to brain stimulation reward (BSR) but less sensitive to 
the effects of drugs that increase extracellular dopamine in behav-
ioral measures of both reward and locomotion. Surprisingly, we 
found increased dopamine release in the mesolimbic system but 
decreased release in the nigrostriatal system. These changes in 
dopaminergic function were not accounted for by differences in 
dopaminergic cell number or differences in tyrosine hydroxylase 
levels or dopamine content in the terminal fields of the nucleus 
accumbens (NAc) or dorsal striatum. Our findings raise the pos-
sibility that similar effects on dopaminergic systems may occur 
in humans and may inform ongoing and future clinical trials of 
l-DOPA in individuals with AS.
Results
Ube3am–/p+ mice are more sensitive to rewarding electrical brain stimu-
lation. Activity of mesolimbic dopaminergic neurons in the mid-
brain ventral tegmental area (VTA) is critical for the perception 
of reward (17, 18). To determine whether loss of UBE3A alters 
mesolimbic dopamine function, Ube3am–/p+ and WT mice were 
implanted with stimulating electrodes in the medial forebrain 
bundle (MFB) and trained to perform operant intracranial self-
stimulation (ICSS) by turning a wheel (Supplemental Figure 
1A; supplemental material available online with this article; 
doi:10.1172/JCI61888DS1). Thresholds for perception of BSR 
were determined before and after administration of drugs that 
increase extracellular dopamine levels (Figure 1A). Ube3am–/p+ 
mice showed a leftward shift of the baseline charge-response 
curve (Figure 1B), indicating that these mice required less charge 
than WT littermates to sustain the same degree of wheel turn-
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ing (Figure 1C; U = 59.0, P < 0.001). There was no difference in 
the maximum rate of operant responding between genotypes 
(Figure 1D), demonstrating that voluntary motor function 
required for ICSS was unimpaired in Ube3am–/p+ mice. Ube3am–/p+ 
mice also sustained a lower reward threshold for longer than WT 
littermates (16–30 minutes, P < 0.001; 31–45 minutes, P < 0.001; 
46–60 minutes, P = 0.026; Figure 1E).
Ube3am–/p+ mice are less sensitive to dopaminergic manipulation of BSR. 
Drugs that enhance extracellular dopamine availability increase 
the potency of BSR, measured as a lowered BSR threshold (Sup-
plemental Figure 1, B and C). To determine whether the increase 
in reward sensitivity in Ube3am–/p+ mice was due to changes in 
dopamine neurotransmission, we investigated the effects of phar-
macological manipulation on BSR threshold. The nonselective 
monoamine reuptake blocker, cocaine, similarly lowered BSR 
thresholds in both genotypes at the peak of its effect from 0 to 15 
minutes after i.p. administration (Figure 2, A and B, and Supple-
mental Figure 2A), but the reward-potentiating effects of cocaine 
decayed more slowly in Ube3am–/p+ mice (Figure 2C). Maximum 
operant response rates showed a greater increase following cocaine 
administration in WT mice at 10.0 mg/kg cocaine (31–45 minutes, 
P = 0.028) and 17.0 mg/kg cocaine (31–45 minutes, P = 0.001; Sup-
plemental Figure 3A), indicating that cocaine effects on operant 
motor behavior are reduced in Ube3am–/p+ mice. The highly selective 
dopamine transporter (DAT) blocker GBR 12909 reduced reward 
threshold similarly to cocaine but remained active for over 2 hours 
following administration. GBR 12909 lowered reward threshold 
significantly less in Ube3am–/p+ mice, revealing a more pronounced 
difference in potentiation of BSR than that seen with cocaine 
(10.0 mg/kg, P = 0.002; 17.0 mg/kg, P < 0.001; Figure 1F and Sup-
Figure 1
Ube3am–/p+ mice are more sensitive to BSR but less 
sensitive to dopaminergic potentiation of BSR. (A) 
Representative ICSS rate-frequency curves in a WT 
mouse. Injection (i.p.) of the DAT antagonist GBR 
12909 dose-dependently increases responding for 
rewarding electrical current at lower stimulus frequen-
cies. (B) Rate-frequency curves expressed as charge 
(Q) delivery at each frequency (Hz) from Ube3am–/p+ 
mice are shifted to the left compared with those of 
WT littermates. (C) Ube3am–/p+ mice require signifi-
cantly less (***P < 0.001) charge to evoke the same 
degree of responding as WT mice at reward threshold 
frequencies (EF50). (D) The maximum rate of operant 
responding for rewarding brain stimulation is compa-
rable between genotypes (P > 0.05). (E) Ube3am–/p+ 
mice maintain a lower reward threshold over time 
(16–30 minutes, ***P < 0.001; 31–45 minutes, 
***P < 0.001; 46–60 minutes, *P = 0.026). (F) WT mice 
exhibit greater potentiation of rewarding brain stim-
ulation expressed as lower reward thresholds than 
Ube3am–/p+ mice following 10.0 mg/kg (**P = 0.002) 
and 17.0 mg/kg (***P < 0.001) GBR 12909 (i.p.). Error 
bars indicate ± SEM in B, E, and F and the median 
and interquartile ranges in C and D.
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plemental Figure 2B). The ability of GBR 12909 to increase the 
maximum operant response rate was also reduced in Ube3am–/p+ 
mice at 10.0 mg/kg (76–90 minutes, P = 0.032; 91–105 minutes, 
P = 0.018) and 17.0 mg/kg (76–90 minutes, P = 0.015; 91–105 minutes, 
P = 0.004; Supplemental Figure 3B).
To assess possible differences in dopamine receptor sensitivity 
in the NAc and other forebrain targets, we measured the potency 
of selective dopamine receptor antagonists in reducing BSR. We 
found that the D1 receptor antagonist SCH 23390 elevated BSR 
thresholds similarly in both genotypes (Figure 2D and Supple-
mental Figure 2C). The motor depressant effect of SCH 23390 on 
maximum operant response rate was also similar between WT and 
Ube3am–/p+ mice (Figure 2G and Supplemental Figure 3C), suggest-
ing that dopamine acting through D1 receptors was unaffected by 
loss of UBE3A. The reward threshold-elevating effects of the D2/3 
receptor antagonist raclopride (Figure 2E) and D2-selective recep-
tor antagonist L741,626 (Figure 2F) were also similar 
between genotypes (see also Supplemental Figure 2, D 
and E). However, the depressant effect of both raclopride 
(16–30 minutes, 0.178 mg/kg, P = 0.005; 0.3 mg/kg, 
P < 0.001; Figure 2H and Supplemental Figure 3D) and 
L741,626 (46–60 minutes, 5.6 mg/kg, P < 0.001; Figure 
2I and Supplemental Figure 3E) on maximum operant 
response rate was blunted in Ube3am–/p+ mice.
Ube3am–/p+ mice are less sensitive to cocaine-stimulated loco-
motor activity. To further assess dopamine-related behav-
ior in Ube3am–/p+ mice, we performed locomotor sensiti-
zation experiments using cocaine (5.6, 10.0, or 17.0 mg/
kg i.p.) as a tool to evaluate both acute locomotor stim-
ulation and adaptation to repeated drug exposure (Fig-
ure 3). Cocaine has a rapid onset of action, with brain 
concentrations peaking approximately 5 minutes after 
injection, and a half-life of approximately 15 minutes 
(19). Therefore, we used the total activity in the first 15 
minutes following injection to compare cocaine-stimu-
lated locomotor activity between genotypes. Total loco-
motion over the 15 minutes following saline injection 
was lower in Ube3am–/p+ mice (531 ± 51 cm) than in WT 
mice (916 ± 79 cm; U = 266, P < 0.001), consistent with 
decreased motor activity previously described in Ube3am–/p+ mice 
(20). Although a low cocaine dose (5.6 mg/kg; Figure 3A) was suffi-
cient in both genotypes to induce locomotor sensitization, defined 
as greater distance traveled on the challenge/last day compared 
with that on the first day of administration (P < 0.001), we found 
Ube3am–/p+ mice to be less sensitized than WT mice (day 4, P = 0.02; 
day 5, P = 0.031; challenge, P = 0.031; Figure 3D). An intermediate 
cocaine dose (10.0 mg/kg; Figure 3B) increased locomotion more 
in WT mice than in Ube3am–/p+ mice for 5 consecutive days after 
the first day of exposure (day 2, P = 0.009; day 3, P = 0.012; days 
4–6, P < 0.001), although this difference was no longer significant 
on cocaine challenge after 7 days (Figure 3E). The largest cocaine 
dose tested (17.0 mg/kg; Figure 3, C and F) stimulated comparable 
locomotion on the second day of exposure in both genotypes, sug-
gesting that the reduced cocaine effect in Ube3am–/p+ mice was not 
due to a reduction in maximum cocaine potency or a ceiling effect.
Figure 2
Ube3am–/p+ mice exhibit normal BSR threshold responses to 
cocaine and selective D1 and D2 dopamine receptor antag-
onists but decreased sensitivity to D2-dependent motor 
impairment. BSR threshold was determined following i.p. 
administration of (A–C) cocaine, (D) the D1 receptor antag-
onist SCH 23390, or the D2-selective antagonists (E) raclo-
pride or (F) L741,626. (A–C) Cocaine had similar potency 
on BSR threshold in both genotypes at its peak effect (0–15 
minutes), but its rewarding effects decayed more slowly in 
Ube3am–/p+ mice (46–60 minutes, 10.0 mg/kg, *P = 0.025; 
17.0 mg/kg, #P < 0.001). (D) The D1 antagonist SCH 23390, 
(E) the D2-like antagonist raclopride, or (F) the highly 
D2-selective antagonist L741,626 equally elevated reward 
thresholds of WT and mutant mice. (G) However, while D1 
receptor antagonism had similar depressant effects on max-
imum operant response rates of both genotypes, antago-
nism of D2 receptors with either (H) raclopride (0.178 mg/kg, 
**P = 0.005; 0.3 mg/kg, #P < 0.001) or (I) L741,626 (5.6 mg/
kg, #P < 0.001) had greater depressant effects on maximum 
response rates of WT mice. Error bars indicate ± SEM.
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Neuroanatomical and biochemical markers of dopamine are unal-
tered in Ube3am–/p+ mice. Projection neurons within the VTA and 
SNc express both UBE3A and tyrosine hydroxylase (TH), the 
rate-limiting enzyme in dopamine biosynthesis. We performed 
immunohistochemistry to confirm maternal imprinting of Ube3a 
in the VTA and SNc (Figure 4A) and then quantified TH-positive 
neurons with design-based stereology in the VTA and SNc. We 
found no differences in the estimated dopamine cell number in 
either region at P100 (Table 1 and Figure 4B). We performed West-
ern blots for TH in the NAc and dorsal striatum as a measure of 
biosynthetic capacity in dopaminergic terminal fields originating 
from neurons in the VTA or SNc, respectively. TH protein levels 
were similar between Ube3am–/p+ and WT mice in the NAc and 
striatum (Table 2 and Figure 4C). HPLC on tissue homogenates 
showed no difference in total dopamine content in Ube3am–/p+ mice 
in the NAc or dorsal striatum (Table 2 and Figure 4D). Further-
more, tissue concentrations of DOPAC, the primary acid metab-
olite of dopamine (Figure 4E), and dopamine/DOPAC concentra-
tion ratios (Figure 4F) were comparable between genotypes.
Dopamine transmission is enhanced in the NAc and reduced in the dor-
sal striatum of Ube3am–/p+ mice. We performed fast-scan cyclic vol-
tammetry (FSCV) in the NAc and dorsal striatum to determine 
whether the loss of UBE3A affected phasic dopamine transmis-
sion in these limbic and motor terminal regions, respectively 
Figure 3
Cocaine-stimulated locomotion 
is lower in Ube3am–/p+ mice. Psy-
chostimulant-induced locomotion 
in 3 separate groups of mice (12 
WT and 12 Ube3am–/p+ mice per 
group) injected with 5.6, 10.0 or 
17.0 mg/kg i.p. cocaine for 6 con-
secutive days and a final chal-
lenge dose 1 week later. (A–C) 
Distance traveled is binned in 
1-minute increments. (D–F) The 
sum of the first 15 minutes fol-
lowing injection is plotted below 
each of their respective treatment 
groups. (D) A deficit in the loco-
motive response of Ube3am–/p+ 
mice emerges after 3 days of 
5.6 mg/kg cocaine administra-
tion (P = 0.02; day 5, P = 0.031; 
challenge, P = 0.031) and (E) 
by the second day of 10.0 mg/
kg cocaine (P = 0.009; day 3, 
P = 0.012; day 4–6, P < 0.001). (F) 
High-dose (17.0 mg/kg) cocaine 
elicits an attenuated response 
after the first administration in 
Ube3am–/p+ mice that is gone by 
the fourth day. (D–F) Cocaine-in-
duced sensitization occurred at all 
3 doses for both genotypes (day 1 
vs. challenge, P < 0.001). Error 
bars indicate SEM. *P < 0.05; 
#P < 0.01; †P < 0.001.
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(Figure 5). Stimulation of the MFB resulted in greater dopamine 
release in the NAc of Ube3am–/p+ mice across all stimulus frequen-
cies (Figure 5A and Supplemental Figure 4A), with higher max-
imum extracellular dopamine concentrations obtained at 30 to 
60 Hz (30 Hz, P = 0.05; 40 Hz, P = 0.008; 50 Hz, P = 0.045; 60 
Hz, P = 0.004; Figure 5, C, E, and G). In contrast to that in the 
NAc, we found reduced dopamine release across all stimulus fre-
quencies (Figure 5B and Supplemental Figure 4B), with lower 
maximum extracellular dopamine concentration in the dorsal 
striatum of Ube3am–/p+ mice at 30 to 50 Hz (30 Hz, P = 0.006; 40 
Hz, P = 0.002; 50 Hz, P = 0.015; Figure 5, D, F, and H). Model-
ing of the FSCV data did not reveal any differences in dopamine 
uptake following stimulation in either the NAc or dorsal striatum 
(data not shown). Administration of the DAT blocker GBR 12909 
prior to stimulation caused similar changes to the time course 
of extracellular dopamine concentrations in the NAc and dorsal 
striatum (Figure 5, I and J), suggesting no differences in dopa-
mine reuptake between genotypes.
Discussion
The principal findings of this study are that Ube3am–/p+ mice, a 
model of AS, exhibit increased mesolimbic dopamine release but 
decreased nigrostriatal dopamine release and decreased behavioral 
sensitivity to drugs that enhance extracellular dopamine avail-
ability. Release of accumbal dopamine is critical to the rewarding 
effects associated with both BSR and drugs of abuse as well as 
natural incentives such as food and sex (21). We used ICSS as an 
experimental model to directly assess motivation and reward and 
Figure 4
Biochemical and anatomical markers 
of the mesolimbic and nigrostriatal 
dopaminergic pathways are normal 
in Ube3am–/p+ mice. (A) Immuno histo-
chemistry showing imprinting of UBE3A 
in the mesencephalic VTA and SNc and 
colocalization with TH in WT mice (orig-
inal magnification, ×4). Boxed regions 
are shown at higher magnification in 
the second, third, and fourth columns 
(original magnification, ×40). (B) Num-
bers of TH-positive cells in the VTA and 
SNc estimated with design-based ste-
reology show no differences between 
WT and Ube3am–/p+ mice. Ventral mid-
brain image is magnified (original mag-
nification, ×4) and the boxed region is 
shown at higher magnification to the 
right (original magnification, ×40). (C) 
Quantification of TH, the rate-limiting 
enzyme in dopamine biosynthesis, 
from NAc and striatal tissue punches 
by immunoblotting shows similar levels 
between the 2 genotypes. (D) HPLC 
analysis of concentrations of dopamine 
and (E) its primary acid metabolite 
DOPAC in NAc and striatal punches 
from WT and Ube3am–/p+ mice shows 
similar tissue content of dopamine and 
DOPAC. (F) Dopamine/DOPAC ratios 
are also equivalent between genotypes 
in NAc and striatum. Error bars indicate 
SEM. Numbers in bars represent num-
bers of mice.
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to minimize effects from potential sensory processing abnormali-
ties (18, 22). We found that Ube3am–/p+ mice required significantly 
less electrical stimulation to attain the same level of responding 
for BSR as in controls and were able to maintain a higher degree 
of responding for BSR over time, consistent with the increased 
dopamine release in the NAc following MFB stimulation that 
we observed with FSCV. Increased extracellular dopamine could 
result from slower dopamine uptake, but no differences in accum-
bal dopamine clearance were observed with FSCV by either model-
ing of uptake kinetics or by administration of GBR 12909, a selec-
tive DAT blocker. This suggests that the increase in extracellular 
dopamine in the NAc is the result of increased release. However, 
Ube3am–/p+ mice were also less sensitive to the reward-potentiat-
ing effects of the DAT-selective reuptake blocker GBR 12909 on 
BSR. While this suggests that loss of UBE3A may affect dopamine 
receptor signaling in the NAc, the attenuated response could not 
be accounted for by differences in D1 or D2 receptor activity, since 
antagonism of both receptors elevated reward thresholds equally 
in both genotypes.
In contrast to that in the NAc, electrically stimulated extracellular 
dopamine was significantly reduced in the dorsal striatum of 
Ube3am–/p+ mice. As in that in the NAc, we observed no differences 
in striatal dopamine clearance with FSCV by either modeling 
of uptake kinetics or by administration of GBR 12909, indicat-
ing normal DAT function. This suggests that extracellular levels 
of dopamine are lower in dorsal striatum as a result of reduced 
release. One of the primary local regulators of dopamine release 
is negative feedback through D2 autoreceptors on dopaminergic 
terminals. Although D2 antagonism did not differentially affect 
BSR threshold in Ube3am–/p+ mice, the inhibitory potencies of both 
the D2/D3 antagonist raclopride and the D2-selective antagonist 
L741,626 in reducing maximum operant response rate were sig-
nificantly lower, suggesting decreased D2 receptor function. Mice 
lacking D2 receptors exhibit some similarities to Ube3am–/p+ mice, 
including decreased cocaine-stimulated locomotion (23, 24) and 
increased extracellular dopamine in the NAc 
following MFB stimulation (25), the latter 
effect due to decreased D2 autoreceptor func-
tion (26). However, in contrast to Ube3am–/p+ 
mice, D2-deficient mice are also less sensi-
tive to BSR alone (27), suggesting that the 
increased sensitivity to BSR and the changes 
in dopamine release in the NAc and dor-
sal striatum that we observed in Ube3am–/p+ 
mice may be due to alterations in other sig-
naling pathways not yet investigated.
Interestingly, some of the changes that we 
observed in Ube3am–/p+ mice resemble those 
found in mouse models of human muta-
tions in patients with autosomal recessive familial 
Parkinson’s disease. Mice lacking either PTEN-in-
duced kinase 1 (Pink1, also known as Park6; ref. 28) 
or the novel glyoxylase DJ-1 (Park7; refs. 29, 30) 
exhibit decreased electrically evoked striatal dopa-
mine release in the absence of changes in dopa-
minergic cell number or dopamine synthesis and 
metabolism. Decreased spontaneous locomotion 
is observed with both mutations but is not evi-
dent in PINK1-deficient mice until late adulthood 
(31). Conversely, mice deficient in the E3 ubiquitin 
ligase parkin (Park2) exhibit increased striatal dopamine release 
while also showing decreases in both spontaneous and drug-stim-
ulated locomotion without changes in dopaminergic cell number, 
striatal TH, or striatal dopamine content (32, 33). In contrast to 
loss of UBE3A, in which dopamine reuptake appears to be func-
tionally normal, loss of either PINK1 or parkin is associated with 
decreased striatal DAT levels and function, while mice deficient 
in DJ-1 have normal DAT levels but increased dopamine reuptake 
and decreased behavioral and physiological sensitivity to D2 recep-
tor agonists (30). Of note, while radionuclide imaging has con-
firmed loss of presynaptic dopamine in the striatum of patients 
with PINK1- (34), DJ-1– (35), and parkin-associated early-onset 
Parkinson’s disease (36), no similar imaging findings or clinical 
measures of monoamines and their metabolites in cerebrospinal 
fluid have been published in studies of patients with AS.
Converging lines of evidence suggest that defects of the ubiq-
uitin-proteasome pathway may underlie some forms of human 
movement disorders, particularly those involving neurodegener-
ative processes (37). For example, some early-onset forms of Par-
kinson’s disease are caused by loss-of-function mutations in genes 
encoding parkin, PINK1, and DJ-1, while mutations in the gene 
encoding α-synuclein (SNCA) have been found in both autosomal 
dominant and sporadic forms of the disease. As mentioned, parkin 
itself is an E3 ubiquitin ligase, which together with PINK1 and 
DJ-1 forms a complex to promote ubiquitination and degradation 
of parkin substrates (38). Parkin has been shown to specifically 
ubiquitinate and increase proteasomal turnover of a number of 
proteins, including O-glycosylated α-synuclein (αSp22; ref. 39), 
which when overexpressed are toxic to monoaminergic neurons 
(40–44). Misfolded α-synuclein or excessive levels of α-synuclein 
are associated with dopaminergic cell death in Parkinson’s dis-
ease and can inhibit ubiquitin-proteasomal activity (45, 46). Data 
from cell culture suggest that α-synuclein may be a substrate for 
UBE3A, but there is no evidence for elevated α-synuclein levels 
in the absence of UBE3A in vivo (47), consistent with normal 
Table 1
Anatomical markers of dopamine
 VTA Substantia nigra
 WT Ube3am–/p+ WT Ube3am–/p+
TH+ cell no. 6,986 ± 427.9 6,645 ± 174.9 5,754 ± 500.2 5,245 ± 182.2
 (n = 6) (n = 5) (n = 6) (n = 5)
No significant genotype differences were found (mean ± SEM).
Table 2
Biochemical markers of dopamine
 NAc Dorsal striatum
 WT Ube3am–/p+ WT Ube3am–/p+
TH protein (% WT) 100 ± 10.99 116.8 ± 13.89 100 ± 6.16 102.9 ± 11.10
 (n = 8) (n = 8) (n = 8) (n = 8)
Dopamine (nmol/g) 23.72 ± 2.49 25.13 ± 2.52 46.93 ± 5.60 40.93 ± 4.63
DOPAC (nmol/g) 1.98 ± 0.51 2.46 ± 0.55 3.37 ± 0.93 3.15 ± 0.64
Dopamine/DOPAC 0.091 ± 0.03 0.100 ± 0.02 0.071 ± 0.02 0.073 ± 0.01
 (n = 5) (n = 5) (n = 5) (n = 5)
No significant genotype differences were found (mean ± SEM).
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numbers of midbrain dopaminergic neurons in 
Ube3am–/p+ mice. Increasing α-synuclein expres-
sion reduces dopamine release by interfering 
with vesicle recycling before neurodegeneration 
occurs, consistent with the reduced dorsal stria-
tal dopamine release we observed in Ube3am–/p+ 
mice (48). It has been shown that dopaminergic 
VTA neurons are resistant to the toxic effects 
of α-synuclein overexpression (49), but it is 
unknown whether or how α-synuclein affects 
dopamine release in the NAc. In light of these 
observations, our data further support the pos-
sibility that disorders of ubiquitination can lead 
to functional changes in neural circuits in the 
absence of neurodegeneration (50, 51).
l-DOPA is a mainstay of therapy for Parkin-
son’s disease but can be accompanied by signifi-
cant adverse effects. For example, patients with 
early-onset Parkinson’s disease with parkin 
mutations are exquisitely sensitive to l-DOPA 
but are also significantly more likely to develop 
limiting dyskinesias and psychiatric complica-
tions while on l-DOPA therapy (52). In patients 
with Parkinsonism, replacement therapy with 
l-DOPA or directly acting dopaminergic ago-
nists is aimed at ameliorating motor symptoms 
mediated by the dorsal striatum. However, such 
therapy consistently leads to adverse effects on 
reward-mediated behaviors involving the NAc 
(53). These observations, together with our 
findings that dopaminergic dysfunction in 
AS may be pathway specific, raise a cautionary 
note for ongoing clinical trials of l-DOPA in 
Figure 5
Dopamine release is enhanced in NAc and reduced 
in dorsal striatum of Ube3am–/p+ mice. Comparison 
of dopamine (DA) release measured with in vivo 
FSCV in the (A) NAc (on left throughout) and (B) 
dorsal striatum (on right throughout) of Ube3am–/p+ 
mice and their WT littermates. (A and B) Traces rep-
resent changes in dopamine concentration evoked 
by 60-Hz stimulation (stimulus duration shaded 
gray). Insets show peak concentration of evoked 
dopamine in individual animals. (C and D) Average 
of peak concentrations evoked by stimulation fre-
quencies, ranging from 20 to 60 Hz (NAc, 30 Hz, 
P = 0.05; 40 Hz, P = 0.008; 50 Hz, P = 0.045; 60 
Hz, P = 0.004; striatum, 30 Hz, P = 0.006; 40 Hz, 
P = 0.002; 50 Hz, P = 0.015). (E–H) Extracellular 
dopamine concentrations following 5 discrete fre-
quency stimulation steps, ranging from 20 to 60 Hz 
in the (E and G) NAc or (F and H) dorsal striatum. 
(I and J) Response of electrically stimulated (60 
Hz) dopamine release to GBR 12909 (20 mg/kg), 
30 minutes after i.p. injection. Insets show the rela-
tive increase in dopamine release (area under the 
curve) following GBR 12909. Error bars indicate 
SEM. Numbers in bars represent numbers of mice. 
*P < 0.05; #P < 0.01; †P < 0.001.
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individuals with AS. Such studies may benefit from additional 
outcome measures, particularly neuropsychiatric indices, to 
ensure that l-DOPA treatment does not lead to unanticipated 
outcomes in patients with AS.
Methods
Animals. Male C57BL6/J WT and maternally deficient Ube3am–/p+ mice were 
used in all instances. These mice were generated from pairings of paternally 
deficient females with WT males. Age of mice ranged from P90 to P120. 
Mice used for ICSS were implanted at P65.7 ± 7.8 days and fully trained 
for the start of behavioral assessment with cocaine at P105.5 ± 18.1 days; 
raclopride at P131.3 ± 17.9 days; L741,626 at P155.3 ± 16.7 days; SCH 
23390 at P164.5 ± 16.2 days; or GBR 12909 at P197.3 ± 12.7 days. Animals 
were kept on a 12-hour-dark/light cycle and given ad libitum access to food 
and water. All experiments (with the exception of Western blots) were per-
formed blinded to genotype.
ICSS. ICSS was performed as detailed previously (54). Briefly, mice (26 
WT and 27 Ube3am–/p+ mice) were anesthetized (120 mg/kg ketamine, 
9 mg/kg xylazine; Hospira), and 0.25% bupivacaine (Hospira) was applied 
to the scalp incision site. A stainless steel monopolar stimulating electrode 
(0.28-mm diameter; Plastics One) was stereotaxically implanted into the 
MFB at the following coordinates relative to bregma: anterior/posterior 
(A/P)  –1.3 mm; medial/lateral (M/L) +1.1 mm; dorsal/ventral (D/V) from 
skull surface –5.0 mm (55). Stimulating electrodes were insulated with 
polyamide, leaving approximately 0.25 mm of the tip exposed. The elec-
trical ground was an uninsulated stainless steel wire (0.125-mm diameter) 
wrapped around a stainless steel screw threaded into the skull. Electrode 
assemblies were secured to the skull with dental cement.
Following 1 week of recovery, mice were trained on a continuous (FR-1) 
schedule of reinforcement by the delivery of rewarding electrical stimu-
lation (BSR) in a sound-attenuated operant chamber (Med Associates) 
equipped with a wheel manipulandum. Each quarter turn of the wheel 
was reinforced by 500 ms of unipolar cathodal square-wave current paired 
with illumination of the house light as a secondary reinforcer. Mice were 
presented 15 descending stimulation frequencies in discrete 0.05 inverse 
log steps, ranging from 126 to 25 Hz (100-μs pulse width). Each fre-
quency trial lasted 1 minute and consisted of a 5-second priming phase 
of noncontingent stimulation; 50-second active phase, during which BSR 
was available; and ended with a 5-second time out, during which further 
responses received no additional stimulation. The minimum current 
intensity required to maintain responding (minimum of 40 responses per 
minute) for the highest 3 to 5 frequencies was determined for each individ-
ual mouse and kept constant for the duration of the experiment. For SCH 
23390, raclopride, and L741,626 experiments, the current was adjusted to 
maintain responding for the top 8–12 frequencies. Each test session con-
sisted of 45 minutes (15 frequencies for 3 repetitions) before injection and 
60 minutes after injection. For GBR 12909 and L741,626, mice were placed 
into their home cage for 30 minutes following injection, followed by either 
90 minutes (6 series repetitions for GBR 12909) or 75 minutes (5 series 
repetitions for L741,626) of access to BSR. BSR thresholds before injection 
(50% of maximum asymptotic response rate [EF50]) were calculated from 
the average of the second and third series (the first series was considered a 
“warm-up” and was discarded) and used as daily baselines for comparison 
to BSR thresholds after injection.
Changes in BSR threshold were evaluated following i.p. injection of 
cocaine (1.0, 3.0, 5.6, 10.0, 17.0 mg/kg, calculated as the free base; 26 WT 
and 27 Ube3am–/p+ mice; Sigma-Aldrich), raclopride (0.03, 0.1, 0.178, 0.3 
mg/kg; 9 WT and 12 Ube3am–/p+ mice; Sigma-Aldrich), L741,626 (1.0, 1.78, 
3.0, 5.6 mg/kg; 6 WT and 9 Ube3am–/p+ mice; Sigma-Aldrich); SCH 23390 
(0.003, 0.01, 0.03, 0.1 mg/kg; 8 WT and 12 Ube3am–/p+ mice; Sigma-Aldrich); 
GBR 12909 (1.0, 3.0, 10.0, 17.0 mg/kg; 7 WT and 9 Ube3am–/p+ mice; 
Sigma-Aldrich); and normal saline or distilled water (vehicle for 741,626). 
All mice were assessed with cocaine and then divided into 2 groups, with 
one group of mice being tested with raclopride and L741,626 and the other 
group being tested with SCH 23390 and GBR 12900. Each dose was repli-
cated 1–2 times and averaged for each mouse’s behavioral response.
Locomotor behavior. Locomotion was measured in unlit sound-attenuated 
chambers (27.3 cm × 27.3 cm; Med Associates) and quantified by beam 
breaks of a 16 × 16 photobeam infrared array. Mice were placed in the 
chamber for 15 minutes of habituation, injected i.p. with normal saline 
or cocaine, and locomotion after injection was monitored for 45 minutes. 
Animals were habituated to the chamber and injection stress (saline) for 
4 days, and the fourth day was used as baseline locomotor activity. Following 
baseline determination, mice were injected with cocaine daily, and cocaine-
stimulated locomotor activity was assessed for 6 consecutive days. Follow-
ing 6 days of cocaine abstinence, during which animals remained in their 
home cages, locomotion after cocaine challenge was evaluated on day 7. 
36 WT and 36 Ube3am–/p+ mice were divided into 3 separate groups of 12, 
receiving either sensitizing doses of 5.6, 10.0, or 17.0 mg/kg cocaine for the 
entirety of the experiment.
TH immunohistochemistry. Mice (6 WT and 5 Ube3am–/p+ mice) were deeply 
anesthetized (120 mg/kg pentobarbital, i.p.) and perfused transcardi-
ally with 0.1 M PBS (pH 7.4), followed by 4% paraformaldehyde in 0.1 M 
PBS. All brains were post-fixed by submersion in the same fixative for 
24 hours and then cryoprotected in 10% sucrose for 24 hours followed 
by 30% sucrose for 24 hours. Brains were sectioned (40 μm, coronal) on 
a sliding microtome and stored in cryoprotectant (1.0% polyvinylpyrroli-
done [w/v], 30% sucrose [w/v], and 30% ethylene glycol [v/v] in 0.1 M PBS). 
Endogenous peroxidase activity was quenched with 1% hydrogen peroxide 
in 0.1 M PBS for 30 minutes at room temperature. Sections were blocked 
in 5% normal goat serum (NGS) and 2% Triton X-100 in 0.1 M PBS for 24 
hours at room temperature and then incubated in rabbit α-rat TH primary 
antibody (1:2,000; AB152, Millipore) in 2% NGS and 2% Triton for 4 days 
at 4°C. Sections were washed (3 times) in 0.1 M PBS and incubated with 
HRP-conjugated goat α-rabbit secondary antibody (1:250; 31460, Thermo 
Scientific) in 2% NGS and 2% Triton at room temperature for 3 hours. 
Reaction product was visualized with a DAB Peroxidase Substrate Kit (SK-
4100; Vector Laboratories). Sections were mounted on potassium dichro-
mate/gelatin-subbed slides and counterstained with cresyl violet for Nissl.
Stereological quantification of cell numbers. The total number of TH-positive 
cells in the SNc and VTA was estimated with design-based stereology using 
StereoInvestigator v9.14 (MBF Bioscience) on a Microphot FXA microscope 
(Nikon). Every other section (section interval = 2) was immunostained and 
counted, yielding on average 12 midbrain sections per animal. The borders 
of the SNc and the VTA at all rostrocaudal levels in the midbrain were delin-
eated at low (×4) magnification based on the standard mouse atlas (55). For 
purposes of this study, the VTA and SNc were divided by a line connecting 
the medial border of the medial lemniscus, dorsally, to the medial edge of 
the corticospinal tract, ventrally, in all sections. Counting frames (50 μm 
× 50 μm) were randomly placed and systematically moved through a sam-
pling grid (120 μm × 120 μm) by the software via a motorized stage (Ludl 
Electronic Products). An optical disector height of 12.0 μm, flanked by 
2.0-μm guard zones on top and bottom, was applied to all counting frames 
based on average section shrinkage estimates. Bright-field counting under 
direct visualization was performed at ×100 oil magnification (NA = 1.4). 
Estimates of the total numbers of TH-immunostained neurons were cal-
culated using the optical fractionator method (56). For all estimates, coef-
ficients of error ≤ 0.10 were accepted (57). Using this protocol, results were 
obtained that are in agreement with estimates of numbers of dopaminergic 
SNc neurons in C57BL6/J mice using other methods (58).
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in either the NAc (from bregma, A/P +1.1, M/L +1.2, D/V from skull surface 
–3.5 to –4.0) or dorsal striatum (from bregma, A/P +0.5, M/L +2.5, D/V from 
skull surface –2.5 to –3.0) (55). A bipolar stainless steel stimulating elec-
trode, insulated to the tip (0.2-mm diameter; Plastics One), was implanted 
into the MFB (bregma, A/P –1.2, M/L +1.0, D/V from skull surface –5.0), 
and an Ag/AgCl reference electrode was implanted into the contralateral 
hemisphere. Computer-generated biphasic pulse trains, 2 ms in width and 
325 μA each phase, were applied through constant current stimulators (NL 
800A; Neurolog, Medical Systems Corp.), for 24 pulses at 20, 30, 40, 50, and 
60 Hz to evoke dopamine release. Stimulation-evoked release was recorded 
during and after the stimulation. GBR 12909 (20 mg/mg, Sigma-Aldrich) 
was dissolved in saline and injected i.p. at a volume of 1 ml/kg.
Glass-encased, cylindrical carbon-fiber microelectrodes and Ag/AgCl 
reference electrodes were prepared as described previously (60). Briefly, 
carbon-fiber microelectrodes were constructed by vacuum aspiration of 
a single T-650 carbon fiber (Thornel, Amoco Co.) into a glass capillary of 
0.6-mm external diameter and 0.4-mm internal diameter (A-M Systems, 
Inc.). A micropipette puller (Narishige) was used to taper the glass and form 
a carbon-glass seal. The exposed carbon fiber was cut to approximately 100 
μm in length and was soaked for 30 minutes in isopropyl alcohol to clean 
the surface. Application of the voltage waveform and data collection for 
FSCV were computer controlled and have been described in detail previ-
ously (61). Briefly, a triangular scan (−0.4 to +1.3 V, 400 V/s) was repeated 
every 100 ms. Data were digitized and stored on a computer using software 
written in LABVIEW (National Instruments). Background-subtracted cyclic 
voltammograms were obtained by digitally subtracting voltammograms 
collected during baseline recording from those collected during stimula-
tion. A custom-built UEI potentiostat (Department of Chemistry Electron-
ics Facility, University of North Carolina at Chapel Hill) was used. All poten-
tials are reported compared with the Ag/AgCl reference electrode. Signal 
processing (background subtraction, signal averaging, and digital filtering) 
(4-pole Bessel Filter, 2 kHz) was also performed by the software. All signals 
were verified as dopaminergic by the shape of their cyclic voltammogram 
as well as by their response to GBR 12909, a selective inhibitor of the DAT. 
Data were analyzed and plotted using TH-1 software.
ICSS and FSCV electrode placement verification. Mice used for ICSS were 
deeply anesthetized with sodium pentobarbital and intracardially perfused 
with 0.9% saline followed by 4% paraformaldehyde in 0.1 M PBS. Mice used 
for FSCV were anesthetized with sodium pentobarbital, and brains were 
removed and drop fixed in 4% paraformaldehyde in 0.1 M PBS. The brains 
were sectioned (50 μm) on a sliding microtome, stained with cresyl violet 
for Nissl, and viewed under low-powered (×4) light microscopy to deter-
mine the location of the most ventral electrode tip placements (Supple-
mental Figures 5 and 6).
Statistics. SigmaPlot (Systat Software) was used for statistical analysis. 
Mann-Whitney tests were run to compare baseline reward thresholds 
(EF50), baseline maximum response rates, or basal locomotor activity 
between genotypes. All other comparisons were based on a repeated-mea-
sures model that included a genotype-by-dose (ICSS), genotype-by-day 
(locomotor activity), genotype-by-second (FSCV), or genotype-by-stimu-
lation frequency (FSCV) interaction. All genotype contrasts (Holm-Sidak) 
were performed based on these models and reported when significant. 
An additional comparison between day 1 and challenge was performed 
for locomotor activity experiments to determine whether sensitization 
occurred. Corrections for multiple comparisons were made for FSCV 
experiments based on the genotype-by-second model. Level of significance 
for all reported effects was placed at P < 0.05.
Study approval. All experimental animal procedures were carried out 
according to the NIH Guide for the Care and Use of Laboratory Animals and the 
Society for Neuroscience Policy on the Use of Animals in Neuroscience Research 
TH and Ube3a immunofluorescence colocalization. 2 WT and 2 Ube3am–/p+ mice 
were transcardially perfused with 4% paraformaldehyde, and their brains 
were post-fixed, cryoprotected, and sectioned on a sliding microtome as 
described above. Tissue sections were rinsed thoroughly in Tris-buffered 
saline plus 0.3% Triton X-100 (TBST, pH 7.5) prior to being incubated at 
80°C for 20 minutes in 10 mM sodium citrate buffer (pH 6.0) for antigen 
retrieval. Subsequently, sections were rinsed in TBST and blocked for 25 
minutes in TBST containing 4% nonfat dry milk. Blocked sections were 
then incubated for 2 days at 4°C in the same blocking solution containing 
sheep anti-TH (1:1,000; Pel-Freez) and mouse anti-Ube3a (1:200; clone 330, 
Sigma-Aldrich) primary antibodies. Sections were then rinsed with fresh 
blocking solution prior to incubation for 1 hour at room temperature in 
biotinylated donkey anti-mouse IgG (1:250; Jackson ImmunoResearch Lab-
oratories Inc.) and Alexa Fluor 488 donkey anti-sheep secondary antibodies 
(Invitrogen). Following several rinses in TBST, sections were incubated for 
1 hour at room temperature in Alexa Fluor 568–streptavidin (2 μg/ml in 
TBST). Tissue was mounted on subbed slides and coverslipped with DPX. 
Images were taken using confocal microscopy (LSM710, Zeiss).
Tissue punches. Mice were deeply anesthetized with sodium pentobarbi-
tal, and brains were snap frozen in methylbutane on dry ice. Brains were 
serially sectioned on a cryostat, until reaching the rostral pole of the NAc. 
Tissue punches (pooled from both hemispheres) were taken from the NAc 
and dorsolateral striatum (17 and 15 gauge, respectively). Punches were 
stored at –80°C until use.
Western blotting. Tissue punches from the NAc and striatum (8 WT and 
8 Ube3am–/p+ mice) were treated with 100 μl lysis buffer (50 mM Tris-HCl, 8.0 
pH, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate). 
To assess TH protein levels, 20 μg of total protein lysates from WT and 
Ube3am–/p+ tissue homogenate were separated by 4%–12% SDS-polyacryl-
amide gel electrophoresis. Proteins were then transferred to nitrocellulose 
membranes, and immunoblotting was performed using a sheep anti-TH 
antibody (1:1,000; Pel-Freez), followed by IRDye800CW-conjugated don-
key anti-sheep IgG (1:1,000; Rockland) and mouse anti–β-actin antibody 
(1:1,000; Sigma-Aldrich), followed by Alexa Fluor 680–conjugated goat 
anti-mouse IgG (1:5,000; Invitrogen). Protein bands were visualized by an 
Odyssey system (LI-COR Biosciences). To control for protein loading, TH 
protein levels were normalized to β-actin levels detected in each sample.
HPLC. Tissue punches from the NAc and dorsal striatum (5 WT and 6 
Ube3am–/p+ mice) were weighed and mixed with 200 μl 0.1 N HClO4 contain-
ing 1 μM hydroquinone, the internal standard. Tissue was homogenized 
using a sonic dismembrator (model 60; Fisher Scientific). The homogenate 
was then centrifuged at 10,000 g for 10 minutes, and the supernatant was 
removed and filtered using a 0.2-μm syringe filter (Millex-LG; Millipore). 
HPLC was employed, using a modified method of Mefford et al. (59). 
Briefly, 20 μl injections were made onto a revered-phase column (5 μm, 
4.6 mm × 5 mm; Waters Atlantis). The mobile phase contained 0.1 M citric 
acid, 1 mM sodium hexylsulfate, 0.1 mM EDTA (pH = 3), and 10% metha-
nol as the organic modifier at a flow rate of 1.0 ml/min. Neurotransmitters 
were detected with a thin-layer radial electrochemical cell (BASi) at a poten-
tial of +800 mV vs. the Ag/AgCl reference electrode. Data were collected 
at 60 Hz using a LabVIEW strip chart recorder program (Jorgenson Lab; 
University of North Carolina at Chapel Hill) and homebuilt electronics. 
The peak area of the analyte was ratioed to the peak area of the internal 
standard, and the analyte concentration in the tissue was calculated. Stock 
solutions were made to be 10 mM in 0.1 N HClO4, and response ratios were 
determined daily using 2 μM solution mixtures.
FSCV. Mice (NAc, 11 WT and 8 Ube3am–/p+ mice; dorsal striatum, 7 WT 
and 9 Ube3am–/p+ mice) were anesthetized with urethane (1.5 g/kg body) and 
affixed in a stereotaxic frame (David Kopf Instruments). Stereotaxic crani-
otomies were performed, and a carbon-fiber microelectrode was implanted 
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